Results 111 to 120 of about 19,485 (207)

Cognitive stagnation and executive function deficits in young children with SCN1A+ Dravet syndrome: Detailed characterization of onset, progression, and impact in the ENVISION natural history study

Epilepsia, EarlyView.
Abstract Objective Dravet syndrome (DS) is a developmental and epileptic encephalopathy characterized by drug‐resistant seizures and developmental slowing. Although cognitive and executive function deficits have been described, their early trajectory is not well understood.
Joseph Sullivan, M. Scott Perry, Ingrid E. Scheffer, James Wheless, Susana Boronat, Andreas Brunklaus, Linda Laux, Anup D. Patel, Colin Roberts, Dennis Dlugos, Deborah Holder, Kelly Knupp, Matt Lallas, Steven Phillips, Eric Segal, Dennis Lal, Elaine Wirrell, Sameer Zuberi, Gerard Gioia, Rebecca Shaffer, Madison M. Berl, Mary Wojnaroski, Sarah Christensen, Alexander King, Emma S. James, Maria Candida Vila, Norman Huang, Jacqueline S. Gofshteyn, Salvador Rico   +28 more
wiley   +1 more source

Seizure recurrence after GLP‐1 receptor agonist initiation in adults with epilepsy

Epilepsia, EarlyView.
Abstract Objective To examine whether initiation of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) is associated with seizure recurrence and related outcomes in adults with epilepsy and type 2 diabetes. Methods We conducted a retrospective cohort study using de‐identified electronic health records from the TriNetX Research Network (January 2003 ...
Majd A. AbuAlrob, Abdullah Hussein, Rand Abdellatif, Adham Itbaisha, Khaled Zammar, Boulenouar Mesraoua   +5 more
wiley   +1 more source

Meta‐analysis of genetic mapping studies in mice reveals candidate epilepsy modifier genes that are outside the current drug development landscape

Epilepsia, EarlyView.
Abstract Objective Despite decades of development in anti‐seizure medications, ~30% of individuals remain refractory to all treatments, and none of the existing therapies are disease modifying. Identifying targets outside the current preclinical paradigm is critically important.
Giovanna L. Durante, Anna L. Tyler, Rod C. Scott, Amanda E. Hernan, J. Matthew Mahoney   +4 more
wiley   +1 more source

Comparative effectiveness of long-term anti-obesity medications in routine clinical practice: a retrospective cohort study using real-world data. [PDF]

Transl Clin Pharmacol
Kim CG, Koh JM, Bae KS.
europepmc   +1 more source

Proposed criteria of levels of evidence for co‐occurring epilepsy in people with functional/dissociative seizures

Epilepsia, EarlyView.
Abstract Objective This work was undertaken to describe the level of evidence for co‐occurring epileptic seizures in patients with known functional/dissociative seizures (FDS) using stratification criteria analogous to the International League Against Epilepsy criteria for functional seizures.
Shruti N. Iyer, Zachary Duarte, Gabriela Figueiredo Pucci, Tara Pirnia, Katherine N. McFarlane, Danielle R. Carns, Alex Israel, Kyr Goyette, Brittany Concilus, Nicholas J. Beimer, Page B. Pennell, M. Angela O'Neal, Laura A. Strom, Laura A. Kirkpatrick, Joseph Ta, Carolina Cuello‐Oderiz, Wesley T. Kerr   +16 more
wiley   +1 more source

Medications for essential tremor. [PDF]

Can Fam Physician
Paige A, Moe SS.
europepmc   +1 more source

Treatment approaches in posthypoxic myoclonus: A narrative review with expert opinion

Epilepsia, EarlyView.
Abstract Acute posthypoxic myoclonus (PHM) is a neurological complication that typically emerges within 12–48 h following cardiac arrest, often in comatose patients. It can present as generalized, multifocal, or focal myoclonus and has traditionally been associated with poor prognosis.
Marina Romozzi, Federico Tosto, David García‐Azorín, Luigi Francesco Iannone, Catello Vollono, Paolo Calabresi, Juan Luis Alcala‐Zermeno, Michael R. Sperling   +7 more
wiley   +1 more source

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME (US) study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This study was undertaken to evaluate patient reasons for nonadoption of migraine‐preventive medications. Despite clear recommendations and eligibility criteria for migraine‐preventive treatment by the American Headache Society and the availability of these treatments, many people with migraine are not taking appropriate ...
Jessica Ailani, Rose Okonkwo, Elizabeth Johnston, Helen Hochstetler, Betzaida Martinez, Anthony Zagar, Robert A. Nicholson, Bert B. Vargas, E. Jolanda Muenzel, Richard B. Lipton   +9 more
wiley   +1 more source

Peripheral nerve block in patients with medication-overuse headache: systematic review and meta-analysis. [PDF]

BMC Neurol
Arias-Tello PA, Coronado-Caceres CF, Serrano-Sablich ME, Mantilla G, Goicochea MT, Alarcon-Ruiz CA.   +5 more
europepmc   +1 more source

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source